Diagnostics Channel NavClinical Channel NavInformatics Channel NavCancer Channel NavRegister Nav
MMTC15_Header  
MMTC M Header 
Archived Content

Targeting Cancer Stem Cells in Oncology 

Monday, February 20
 


 

FROM THERAPEUTIC DISCOVERY TO THE CLINIC

8:25 am Chairperson's Remarks

Robert Hollingsworth, Ph.D., Director, Cancer Biology, MedImmune, Inc.

8:30 Targeting Telomeres and Telomerase in Cancer Stem Cells

Calin O. Marian, MS.c., Ph.D., Assistant Professor, Department of Urology, University of Texas Southwestern Medical Center

Evidence has suggested that the capability for tumor recurrence and metastasis resides in cancer stem cells. Current investigation into the role of telomeres and telomerase in cancer stem cells (CSCs) has lead to viable approaches towards targeting telomerase in CSCs.

9:00 Imetelstat as an Inhibitor of Cancer Stem Cells

Martha Blaney, Pharm.D., Medical Director, Geron

Imetelstat is a novel oligonucleotide and a potent inhibitor of telomerase. Preclinical studies suggest that imetelstat  may play a key role in the inhibition of cancer stem cells. Phase II clinical trials are ongoing.

9:30 A Review of Stemline Therapeutic’s Clinical Programs

Eric Rowinsky, M.D., CMO & Head, Research & Development, Stemline Therapeutics, Inc.

10:00 Networking Coffee Break with Poster Viewing

EMERGING CANCER STEM CELL THERAPEUTIC PROGRAMS

10:30 Cancer Stem Cell Therapeutics from a Different Perspective: A Bottom-Up View

Norman J. Maitland, Ph.D., Director, Yorkshire Cancer Research Unit and Department of Biology, University of York, UK

There is currently no long-term treatment for prostate cancer once the tumor has escaped from the prostate and failed hormone treatment. Employing a biology-driven strategy, Pro-Cure Therapeutics has validated novel therapeutic targets, designed to target therapy resistant disease, in proprietary prostate cancer stem cell assays.

10:50 Elimination of Cancer Stem Cells by using Redirected T Cells

Patrick A. Baeuerle, Ph.D., Professor of Immunology, CSO & Senior Vice President, Micromet, Inc.

Cancer stem cells (CSC) appear resistant to anti-proliferative therapies. Temporarily non-dividing CSC can however be eliminated by T cells redirected with the help of bispecific antibodies that are simultaneously binding to a surface target on CSC, and to T cells.

11:10 Immunologic Strategies to Target Cancer Stem Cells

John S. Yu, M.D., Professor & Vice Chairman, Neurosurgery, Cedars-Sinai Medical Center; Chairman & CSO, ImmunoCellular Therapeutics

Recent observations of the laboratory have demonstrated that cancer stem cells are chemoresistant and may be the major reason for the recurrence of these deadly tumors. Hence we have developed novel immunologic strategies to target cancer stem cells.

11:30 Therapeutic Antibodies Targeting Colon Cancer Stem Cells

Christopher Reyes, Ph.D., CSO, Eclipse Therapeutics, Inc.

Eclipse Therapeutics is dedicated to the discovery and development of therapeutics that target cancer stem cells. This presentation will discuss Eclipse's cancer stem cell therapeutic antibody program and provide insights on the development of effective, functional antibodies targeting cancer stem cells.

11:50 Q&A with Emerging Therapeutic Programs

12:00 pm Close of Symposium
 

Day 1 | Day 2 | Download Brochure 

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag 



2014 Premier Sponsors:

 Elsevier   

 

NanoString 

 

Quanterix 

 

RemedyMD 

 

Singulex 

 

Thomson Reuters